GRTS_2021_logoupdate_color.jpg
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
January 13, 2022 07:00 ET | Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...
Logo-uniQure-MS-Word_Orange.jpg
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
December 09, 2021 07:05 ET | uniQure Inc.
~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
October 21, 2021 06:45 ET | BioNTech SE
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In...
Daten aus Phase-3-Studie von Pfizer und BioNTech zeigen hohe Wirksamkeit von COVID-19-Auffrischungsimpfung
October 21, 2021 06:45 ET | BioNTech SE
Die ersten Ergebnisse einer randomisierten, kontrollierten COVID-19 Impfstoff-Auffrischungsstudie zeigen eine relative Impfstoffwirksamkeit von 95,6 % gegen COVID-19 in einem Zeitraum, in dem Delta...
160223 logo Adocia avec homme qui marche.jpg
Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
October 14, 2021 01:30 ET | Adocia SA
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to...
Axsome Logo.png
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
September 16, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
July 19, 2021 01:00 ET | Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
Bone Therapeutics provides update on the progress of clinical studies
July 19, 2021 01:00 ET | Bone Therapeutics SA
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...
Arcutis logo.png
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
July 12, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET | FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...